Strimvelis
autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence
Severe Combined Immunodeficiency
Date of authorisation:
Revision: 10
Last updated:
MedicineHumanAuthorised
Hyftor
sirolimus
Angiofibroma
Tuberous Sclerosis
Date of authorisation:
Revision: 2
Last updated:
MedicineHumanAuthorised
Rapamune
sirolimus
Graft Rejection
Kidney Transplantation
Date of authorisation:
Revision: 46
Last updated:
MedicineHumanAuthorised
Strimvelis - direct healthcare professional communication (DHPC)
Active substance: autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human adenosine deaminase (ADA) cDNA sequence from human haematopoietic stem/progenitor (CD34+) cells
DHPC type:
Adverse event
Last updated:
DHPCHuman
Opsiria
sirolimus
Date of withdrawal:
Last updated:
MedicineHumanWithdrawn application
EMEA-001289-PIP01-12-M01 - paediatric investigation plan
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Immunology-Rheumatology-Transplantation
PIP number: P/0190/2014
Route(s) of administration: Intravenous use
Pharmaceutical form(s):
Cell suspension for infusion
Decision date:
Last updated:
Compliance check: ✔
PIPHuman